Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with
serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory
alternative therapy available for treatment of diabetes, and who are not eligible to
participate in the ongoing pivotal clinical trial (Protocol GEN-084-OL). This protocol is
intended as a substitute for the Single Patient IND mechanism to obtain Generex Oral-lyn™.